Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
August 08, 2017 08:00 ET
|
Esperion Therapeutics, Inc.
– Phase 3 Enrollment Progress Supports NDA Submissions for LDL-C Lowering Indications for Bempedoic Acid / Ezetimibe Combination Pill and Bempedoic Acid by the First Quarter 2019 –– Conference Call...